Provided by Tiger Trade Technology Pte. Ltd.

HUA MEDICINE-B

2.330
+0.0301.30%
Volume:311.00K
Turnover:734.50K
Market Cap:2.46B
PE:2.12
High:2.385
Open:2.375
Low:2.330
Close:2.300
52wk High:4.950
52wk Low:1.970
Shares:1.06B
HK Float Shares:1.06B
Volume Ratio:0.26
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.100
ROE:-10.51%
ROA:-4.53%
PB:2.12
PE(LYR):2.12
PS:3.22

Loading ...

Hua Medicine Releases Interim Report 2026 Online and Outlines Shareholder Communication Options

Bulletin Express
·
Sep 24

Hua Medicine Announces Online Release of 2026 Interim Report; Printed Copies Available Upon Request

Bulletin Express
·
Sep 24

Hua Medicine’s H1 2026 Revenue Jumps 74 % on HuaTangNing Sales; Net Loss Narrows as Gross Margin Climbs

Bulletin Express
·
Sep 24

Hua Medicine Reports Stable Share Capital in August 2026; Minor Option Activity Recorded

Bulletin Express
·
Sep 04

Hua Medicine Grants 200,000 Share Options at HK$ 2.6 Each

Reuters
·
Aug 21

HUA MEDICINE-B (02552) Balances Stability with Progress: HuaTangNing® Commercial Expansion Paves the Way for Global Value Delivery

Stock News
·
Aug 21

HUA MEDICINE-B (02552) Reports Strong Mid-Year Results with Rapid Commercial Growth and Hong Kong-Macau Market Entry

Stock News
·
Aug 20

Hua Medicine: H1 2026 Revenue Jumps 74% to RMB 378.90 Million; Gross Margin Expands to 61.8% While Net Loss Narrows

Bulletin Express
·
Aug 20

Hua Medicine Swings to RMB 30.2 Million H1 FY26 Loss; Revenue Rises 74% to RMB 378.9 Million

Reuters
·
Aug 20

Hua Medicine Sets 20 August 2026 Board Meeting to Review 1H 2026 Interim Results

Bulletin Express
·
Aug 10

Hua Medicine Expects Loss of Rmb30.2 Mln for HY

Reuters
·
Aug 07

Hua Medicine Issues Profit Warning: Expects RMB30.20 Million Interim Loss Without 2025 One-Off Gain

Bulletin Express
·
Aug 07

Hua Medicine Sees Increased Revenue and Improved Gross Profit Margin in Hy

THOMSON REUTERS
·
Aug 07

Hua Medicine - Expects Loss of Rmb30.2 Mln for Hy

THOMSON REUTERS
·
Aug 07

Hua Medicine-B Surges Over 10% as First-in-Class Drug Dorzagliatin Gains Approval in Macau, Expanding Greater Bay Area Market with DKSH

Stock News
·
Jul 02

Hua Medicine's Dorzagliatin Gains Approval in Macau, Expanding Greater Bay Area Presence with DKSH Partnership

Stock News
·
Jun 30

DKSH Expands Partnership with Hua Medicine to Support Hong Kong Diabetes Drug Rollout

Reuters
·
Jun 29

Hua Medicine-B Shares Surge Over 8% as Dorzagliatin Data Presented at ADA and GK Charger AI Platform Advances

Stock News
·
Jun 29

HK Movers | Hong Kong Biotech Sector Strengthened; TRANSTHERA Rose More Than 20%

Tiger Newspress
·
Jun 29

Hua Medicine-B: Shareholders Endorse All AGM Resolutions; Director Re-Elections and New Articles Secure Approval

Bulletin Express
·
Jun 25